KR100912998B1 - Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체 - Google Patents

Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체 Download PDF

Info

Publication number
KR100912998B1
KR100912998B1 KR1020077022281A KR20077022281A KR100912998B1 KR 100912998 B1 KR100912998 B1 KR 100912998B1 KR 1020077022281 A KR1020077022281 A KR 1020077022281A KR 20077022281 A KR20077022281 A KR 20077022281A KR 100912998 B1 KR100912998 B1 KR 100912998B1
Authority
KR
South Korea
Prior art keywords
methyl
compound
chk1
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077022281A
Other languages
English (en)
Korean (ko)
Other versions
KR20070107178A (ko
Inventor
프랭크 디아즈
프랑씬 에스. 파루
라이언 홀콤
에드워드 에이. 케시키
후아 치 오이
알렉산더 루돌프
프랭크 스타펜벡
유진 쏘셋
존 조셉 가우디노
킴바 엘. 피셔
아담 웨이드 쿡
Original Assignee
이코스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이코스 코포레이션 filed Critical 이코스 코포레이션
Publication of KR20070107178A publication Critical patent/KR20070107178A/ko
Application granted granted Critical
Publication of KR100912998B1 publication Critical patent/KR100912998B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
KR1020077022281A 2005-03-29 2006-03-29 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체 Expired - Fee Related KR100912998B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
US60/666,026 2005-03-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002925A Division KR20090031459A (ko) 2005-03-29 2006-03-29 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체

Publications (2)

Publication Number Publication Date
KR20070107178A KR20070107178A (ko) 2007-11-06
KR100912998B1 true KR100912998B1 (ko) 2009-08-20

Family

ID=36677174

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077022281A Expired - Fee Related KR100912998B1 (ko) 2005-03-29 2006-03-29 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체
KR1020097002925A Ceased KR20090031459A (ko) 2005-03-29 2006-03-29 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097002925A Ceased KR20090031459A (ko) 2005-03-29 2006-03-29 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체

Country Status (31)

Country Link
US (1) US8093244B2 (https=)
EP (2) EP1869020B1 (https=)
JP (2) JP5117374B2 (https=)
KR (2) KR100912998B1 (https=)
CN (2) CN101151259B (https=)
AR (1) AR056645A1 (https=)
AT (1) ATE490248T1 (https=)
AU (1) AU2006230337B2 (https=)
BR (1) BRPI0609667A2 (https=)
CA (1) CA2602199C (https=)
CR (1) CR9395A (https=)
CY (1) CY1111240T1 (https=)
DE (1) DE602006018590D1 (https=)
DK (1) DK1869020T3 (https=)
EA (1) EA011287B1 (https=)
ES (1) ES2356068T3 (https=)
HR (1) HRP20100678T1 (https=)
IL (1) IL185481A0 (https=)
MA (1) MA29439B1 (https=)
MX (1) MX2007012116A (https=)
NO (1) NO20074944L (https=)
NZ (1) NZ561458A (https=)
PL (1) PL1869020T3 (https=)
PT (1) PT1869020E (https=)
RS (1) RS51616B (https=)
SI (1) SI1869020T1 (https=)
TN (1) TNSN07369A1 (https=)
TW (1) TWI375559B (https=)
UA (1) UA92164C2 (https=)
WO (1) WO2006105262A1 (https=)
ZA (1) ZA200707715B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
MY150649A (en) * 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
HRP20220351T1 (hr) 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
US20200108074A1 (en) * 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070494A1 (en) 2001-03-02 2002-09-12 Icos Corporation Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers
US20040014765A1 (en) 2002-05-29 2004-01-22 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040259885A1 (en) * 2002-08-13 2004-12-23 Gaoquan Li Urea kinase inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
JP2001518501A (ja) 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
AU2001243226A1 (en) 2000-02-25 2001-09-03 The Regents Of The University Of California Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
CA2434066A1 (en) 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Chromane derivatives, process for their preparation and their use as antitumor agents
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
DE60229975D1 (de) 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1501831A1 (en) 2002-04-26 2005-02-02 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
BR0316680A (pt) 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
CA2512683C (en) 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
EP1765808A1 (en) * 2004-06-25 2007-03-28 ICOS Corporation Bisarylurea derivatives useful for inhibiting chk1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070494A1 (en) 2001-03-02 2002-09-12 Icos Corporation Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers
US20040014765A1 (en) 2002-05-29 2004-01-22 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040259885A1 (en) * 2002-08-13 2004-12-23 Gaoquan Li Urea kinase inhibitors

Also Published As

Publication number Publication date
JP2008535830A (ja) 2008-09-04
EP2330105A1 (en) 2011-06-08
US8093244B2 (en) 2012-01-10
RS51616B (sr) 2011-08-31
EA011287B1 (ru) 2009-02-27
MX2007012116A (es) 2008-04-08
HK1119670A1 (en) 2009-03-13
TW200722090A (en) 2007-06-16
US20090143357A1 (en) 2009-06-04
TWI375559B (en) 2012-11-01
EA200702094A1 (ru) 2008-02-28
UA92164C2 (ru) 2010-10-11
IL185481A0 (en) 2008-01-06
CY1111240T1 (el) 2015-06-11
DE602006018590D1 (de) 2011-01-13
PL1869020T3 (pl) 2011-05-31
CR9395A (es) 2008-03-31
AU2006230337B2 (en) 2011-10-27
JP5117374B2 (ja) 2013-01-16
HRP20100678T1 (hr) 2011-02-28
NZ561458A (en) 2011-03-31
KR20090031459A (ko) 2009-03-25
AU2006230337A1 (en) 2006-10-05
NO20074944L (no) 2007-10-24
CN101151259A (zh) 2008-03-26
CA2602199C (en) 2013-09-10
CN101151259B (zh) 2011-06-15
MA29439B1 (fr) 2008-05-02
SI1869020T1 (sl) 2011-02-28
KR20070107178A (ko) 2007-11-06
WO2006105262A1 (en) 2006-10-05
AR056645A1 (es) 2007-10-17
DK1869020T3 (da) 2011-01-24
ATE490248T1 (de) 2010-12-15
BRPI0609667A2 (pt) 2010-04-20
CN102219784A (zh) 2011-10-19
ES2356068T3 (es) 2011-04-04
TNSN07369A1 (en) 2008-12-31
EP1869020B1 (en) 2010-12-01
EP1869020A1 (en) 2007-12-26
ZA200707715B (en) 2009-09-30
PT1869020E (pt) 2010-12-23
CA2602199A1 (en) 2006-10-05
JP2009227682A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
US7560462B2 (en) Compounds useful for inhibiting CHK1
JP2009227682A (ja) Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体
JP2008535830A5 (https=)
US20080318974A1 (en) Compounds Useful for Inhibiting Chk1
CN101006075A (zh) 可用于抑制chk1的双芳基脲衍生物
HK1119670B (en) Heteroaryl urea derivatives useful for inhibiting chk1

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20130729

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20140730

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20150630

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160813

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160813